CARIBOU BIOSCIENCES I

Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board

06 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

01 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

18 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer

27 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

29 Aug 2023 15:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update

08 Aug 2023 15:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering

13 Jul 2023 22:15:49 By Nasdaq GlobeNewswire

Caribou Biosciences Announces Proposed Public Offering of Common Stock

13 Jul 2023 15:03:00 By Nasdaq GlobeNewswire

Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL

13 Jul 2023 15:01:00 By Nasdaq GlobeNewswire

Caribou Biosciences Announces $25 Million Equity Investment from Pfizer

06 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

31 May 2023 15:00:25 By Nasdaq GlobeNewswire

Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update

09 May 2023 15:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board

08 May 2023 08:00:24 By Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

01 May 2023 15:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting

17 Apr 2023 12:30:00 By Nasdaq GlobeNewswire

Caribou Biosciences Announces FDA Granted Fast Track Designation to CB-011, an Allogeneic CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma

04 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Caribou Biosciences Initiates Dose Expansion Portion of CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients

29 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

29 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

09 Mar 2023 16:09:03 By Nasdaq GlobeNewswire

Caribou Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference

08 Mar 2023 15:05:00 By Nasdaq GlobeNewswire